[{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI-1607","moa":"Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BI-1910","moa":"TNF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Cancer Research"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"SkylineDx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"DS-1055","moa":"Transforming growth factor beta activator LRRC32 (LRRC32)","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent \/ Daiichi Sankyo"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Exelixis"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BioInvent","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Mezagitamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Immunology","graph2":"Phase III","graph3":"BioInvent","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"BioInvent \/ XOMA","highestDevelopmentStatusID":"10","companyTruncated":"BioInvent \/ XOMA"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Cantargia AB","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent \/ Cantargia AB"},{"orgOrder":0,"company":"BioInvent","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Merck & Co"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNF2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI-1607","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by BioInvent
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
